Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410ST—a Modifier Gene Therapy—in GARDian Study for Stargardt Disease
April 01, 2024 18:08 ET
|
Ocugen
Established Low Dose as Safe and Tolerable Dose in Current OCU410ST Clinical TrialDSMB Determination to Proceed with Medium Dose Cohort Dosing MALVERN, Pa., April 01, 2024 (GLOBE NEWSWIRE) --...
Global Ophthalmology EMR Software Market to Reach USD 504.92 Million by 2028 – Extensive Report Analyzes Impact of COVID-19, Market Dynamics, and Competitive Landscape
March 27, 2024 13:06 ET
|
Research and Markets
Dublin, March 27, 2024 (GLOBE NEWSWIRE) -- The "Global Ophthalmology EMR Software Market (2023-2028) Competitive Analysis, Impact of Covid-19, Ansoff Analysis" report has been added to ...
Global Intraocular Lens Market Expected to Reach USD 9.82 Billion by 2034
March 27, 2024 08:40 ET
|
Research and Markets
Dublin, March 27, 2024 (GLOBE NEWSWIRE) -- The "Global Intraocular Lens Market Analysis & Forecast 2024-2034: Market By Product; By Material; By End-user; and By Region" report has been added to...
Global Diabetic Macular Edema Treatment Market by Treatment (Corticosteroid Injections, Drugs, Laser Treatment), End-User (Hospitals, Ophthalmology Clinics) - Forecast 2024-2030
March 19, 2024 17:52 ET
|
Research and Markets
Dublin, March 19, 2024 (GLOBE NEWSWIRE) -- The "Global Diabetic Macular Edema Treatment Market by Treatment (Corticosteroid Injections, Drugs, Laser Treatment), End-User (Hospitals, Ophthalmology...
Global Anterior Uveitis Treatment Market by Treatment Type (Anti-Tumor Necrosis Factor Agents, Corticosteroids, Cycloplegic Agents), Distribution Channel - Forecast 2024-2030
March 19, 2024 17:49 ET
|
Research and Markets
Dublin, March 19, 2024 (GLOBE NEWSWIRE) -- The "Global Anterior Uveitis Treatment Market by Treatment Type (Anti-Tumor Necrosis Factor Agents, Corticosteroids, Cycloplegic Agents), Distribution...
US Retinal Specialists Highlight the Greatest Opportunity for Gene Therapies
March 19, 2024 14:20 ET
|
Spherix Global Insights
EXTON, PA, March 19, 2024 (GLOBE NEWSWIRE) -- Gene therapies have emerged as a ray of hope, particularly in the realm of eye diseases. The focus on the eye has provided researchers with a promising...
Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer
March 18, 2024 07:05 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., March 18, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through...
Ocugen, Inc. Appoints Huma Qamar, MD, MPH as Chief Medical Officer
March 18, 2024 06:30 ET
|
Ocugen
MALVERN, Pa., March 18, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
Medical Biomimetics Market Size is projected to reach USD 54.25 billion by 2031, growing at a CAGR of 6.5%: Straits Research
March 14, 2024 09:20 ET
|
Straits Research Private Limited
New York, United States, March 14, 2024 (GLOBE NEWSWIRE) -- Medical biomimetics, also known as biomimicry or bioinspired technology, is a field that creates and develops novel medical treatments,...
Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410
March 13, 2024 08:00 ET
|
Ocugen
MALVERN, Pa., March 13, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...